Key result
AVE 0991, an orally active nonpeptide Ang-(1-7) receptor Mas agonist, exerts beneficial cardiovascular and renal effects and represents a putative target for new cardiovascular drugs.
Design
Review
Authors
Loading...
Should not change practice; hypothesis-generating for Mas agonism in cardiovascular drug development.
This review highlights the potential of AVE 0991 and the ACE2-Ang-(1-7)-Mas axis as a putative target for the development of new cardiovascular drugs.
Santos et al. (2006) conducted a review in Cardiovascular and renal diseases. AVE 0991 was evaluated. AVE 0991, an orally active nonpeptide Ang-(1-7) receptor Mas agonist, exerts beneficial cardiovascular and renal effects and represents a putative target for new cardiovascular drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: